Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura N Eadie
Observed names:
L Eadie,
L N Eadie,
Laura Eadie,
Laura N. Eadie
Institutions:
South Australian Health and Medical Research Institute,
Adelaide University,
The University of Adelaide
Observed institutions:
South Australia Pathology,
UNSW Sydney,
South Australian Health and Medical Research Institute,
Centre for Cancer Biology,
Adelaide University,
The University of Adelaide
show all 6
ORCID:
0000-0003-1912-7602
Observed ORCID:
0000-0003-1912-7602
OpenAlex ID:
A5023254607
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
2008
·
Devendra K. Hiwase
, Verity Saunders
, et al.
·
Clinical Cancer Research
·
228
Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
2013
·
L N Eadie
, T P Hughes
, et al.
·
Clinical Pharmacology & Therapeutics
·
98
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
2016
·
L N Eadie
, P Dang
, et al.
·
Leukemia
·
75
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
2018
·
Laura N. Eadie
, Verity A. Saunders
, et al.
·
Oncotarget
·
65
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease
2019
·
Michelle O. Forgione
, Barbara J. McClure
, et al.
·
Cancer Letters
·
57
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
2016
·
Laura N. Eadie
, Timothy P. Hughes
, et al.
·
PLoS ONE
·
41
PDF
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments
2025
·
Maxim Buckley
, David T. Yeung
, et al.
·
Leukemia
·
34
PDF
HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort
2021
·
Elyse C. Page
, Susan L. Heatley
, et al.
·
Oncogene
·
32
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
2018
·
Laura N. Eadie
, Phuong Dang
, et al.
·
PLoS ONE
·
29
PDF
MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies
2020
·
Michelle O. Forgione
, Barbara J. McClure
, et al.
·
Genes Chromosomes and Cancer
·
27
Degree of kinase inhibition achievedin vitroby imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
2012
·
Laura N. Eadie
, Verity A. Saunders
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
27
RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)
2022
·
Jacqueline Rehn
, Chelsea Mayoh
, et al.
·
PLoS Genetics
·
22
Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia
2021
·
Paniz Tavakoli Shirazi
, Laura N. Eadie
, et al.
·
Cancer Letters
·
19
CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study
2008
·
Deborah L White
, Verity A Saunders
, et al.
·
Blood
·
19
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL
2019
·
Paniz Tavakoli Shirazi
, Laura N. Eadie
, et al.
·
British Journal of Cancer
·
17
PDF
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
2024
·
Laura N. Eadie
, Elias Lagonik
, et al.
·
Blood
·
15
PDF
Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells
2010
·
L Eadie
, T P Hughes
, et al.
·
Leukemia
·
15
Catalytic Chain Transfer Isomerization Reactions Involving 2-Phenylallyl Alcohol
2001
·
David A. Morrison
, Laura Eadie
, et al.
·
Macromolecules
·
12
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy
2018
·
Laura N Eadie
, Timothy P Hughes
, et al.
·
Leukemia
·
11
Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients
2023
·
Ashlee J. Thomson
, Jacqueline A. Rehn
, et al.
·
Cancers
·
9
PDF
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia
2022
·
Paniz Tavakoli Shirazi
, Laura N. Eadie
, et al.
·
Cancer Gene Therapy
·
7
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells
2012
·
D L White
, L N Eadie
, et al.
·
Leukemia
·
7
Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain
2025
·
Elias Lagonik
, Elyse C. Page
, et al.
·
Blood Neoplasia
·
6
PDF
Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present
2023
·
Laura N Eadie
, Caitlin E Schutz
, et al.
·
Blood
·
6
In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.
2007
·
Devendra K. Hiwase
, Deborah L. White
, et al.
·
Blood
·
6
Show more works
View as search
Works count:
55
Citation count:
934
H-index:
15
I10-index:
19
Year
Topic
Type